Otonomy Provides Corporate and Product Pipeline Update
January 09, 2017 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO® in Patients with Acute Otitis Externa
January 05, 2017 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Cempra to Present at J.P. Morgan Healthcare Conference
January 04, 2017 07:00 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Receives Complete Response Letter From FDA For Solithromycin NDAs
December 29, 2016 06:55 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Dec. 29, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Appoints Dr. David Zaccardelli as Acting Chief Executive Officer, Promotes Chief Commercial Officer David Moore to President
December 12, 2016 09:01 ET
|
Cempra, Inc.
—Leadership changes bolster manufacturing, regulatory and commercial expertise— —Cempra founder, president and CEO, Dr. Prabhavathi Fernandes, announces retirement from the company and...
Toyama Chemical (a Subsidiary of FUJIFILM Holdings Corporation) Begins Phase 3 Studies in Japan With Cempra’s Solithromycin
December 05, 2016 08:00 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Otonomy to Present at Piper Jaffray Healthcare Conference
November 22, 2016 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 22, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
FDA Advisory Committee Votes That Efficacy Results of Cempra’s Solithromycin Outweigh Risks for Community-Acquired Bacterial Pneumonia
November 04, 2016 22:40 ET
|
Cempra, Inc.
—FDA PDUFA dates December 27 & 28, 2016— CHAPEL HILL, N.C., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing...
Cempra Stock Trading Halted Today; FDA Advisory Committee to Discuss Solithromycin
November 04, 2016 07:05 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Otonomy Reports Third Quarter 2016 Financial Results and Provides Corporate Update
November 03, 2016 16:13 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...